Clinical trials: Rifampin
Latent Tuberculosis Infection (LTBI), Tuberculosis (TB)
Latent Infection Freshmen Tracking for Tuberculosis
The goal of this study is to learn whether taking short-course preventive treatment in high school and college freshmen with strong positive tuberculosis (TB) skin tests can safely and effectively protect them from developing…
- Trial name
- LIFT-TB (NCT07811518)
- Testing
- tuberculosis preventive treatment
- Where
- 2 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Nantong University
Tuberculosis
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
A single-center, open-label clinical trial to determine the early bactericidal activity (EBA) and safety of the combination of meropenem and amoxicillin/clavulanate plus pyrazinamide vs.
- Trial name
- TB_COMBO_01 (NCT04629378)
- Testing
- Meropenem Injection, Amoxicillin Clavulanate, Pyrazinamide
- Where
- South Africa
- Volunteers
- 22 people
- Sponsor
- TASK Applied Science
HIV Infection, Pulmonary TB
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Acquired Rifampicin Resistance has emerged as an important issue in the treatment of HIV-TB patients. It has not been a major problem in HIV-negative individuals treated for TB treated with standard intermittent regimens.
- Trial name
- NCT00933790
- Testing
- ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
- Where
- 3 sites in India
- Volunteers
- 331 people
- Sponsor
- Tuberculosis Research Centre, India
Prosthetic-joint Infection, Infection Hip
Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection
In this Dutch multicenter clinical trial, patients with a staphylococcal prosthetic joint infection, will, in the oral antibiotic treatment phase, be randomized between clindamycin monotherapy and rifampicin / levofloxacin…
- Conditions
- Prosthetic-joint Infection, Infection Hip, Infection; Knee, Joint
- Trial name
- RiCOTTA (NCT06172010)
- Testing
- Clindamycin, Rifampicin and levofloxacin
- Where
- 13 sites in Netherlands
- Volunteers
- 316 people
- Sponsor
- Leiden University Medical Center
Healthy Adults
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in…
- Trial name
- NCT05255276
- Testing
- Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mirati Therapeutics Inc.
Hiv, Tuberculosis
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
This is a drug interaction study in HIV negative, TB-monoinfected participants coming to the end of continuation phase of TB therapy, to study the pharmacokinetic changes to dolutegravir when administered with standard, medium…
- Trial name
- DoRIS (NCT04166474)
- Testing
- Dolutegravir
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 36 people
- Sponsor
- Helen Reynolds
Pulmonary Tuberculosis Without Resistance to Rifampicin
Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis
The current standard short-course treatment for pulmonary TB requires 6 months to complete. This long duration of treatment increases the likelihood of side effects while decreasing patients' adherence to anti-TB drugs.
- Trial name
- NCT01994460
- Testing
- Linezolid, Ethambutol
- Where
- 3 sites in South Korea
- Volunteers
- 429 people
- Sponsor
- Seoul National University Hospital
Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once…
- Trial name
- NCT04044001
- Testing
- BTZ-043, Rifafour e-275®, Probe Drug Cocktail
- Where
- 2 sites in South Africa
- Volunteers
- 78 people
- Sponsor
- Michael Hoelscher
Advanced Solid Tumours
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
This is a Phase 1, open-label, non-randomised, 3-arm (A, B, and C), drug-drug interaction study in patients with advanced solid tumours.
- Trial name
- NCT04959266
- Testing
- Adavosertib, Itraconazole, Rifampicin
- Where
- 5 sites in United States, Spain
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Solid Tumor
A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
This study will adopt a Single-center, Single-arm, Open, Fixed Sequence design to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects.
- Trial name
- NCT06619951
- Testing
- VC004 and Itraconazole, VC004 and rifampicin
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Malignancies Multiple
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.
- Trial name
- NCT03346837
- Testing
- BMS-986205, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Tuberculosis, Rifampicin Resistant Tuberculosis
Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a single dose of pretomanid, added to an optimized background tuberculosis treatment regimen (OBR), in children with…
- Trial name
- NCT05586230
- Testing
- Pretomanid, Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)
- Where
- 5 sites in Brazil, South Africa and 1 more
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Fungal Infection
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
This is a Phase 1, open-label study to evaluate the drug-drug interaction potential of a strong CYP3A4 inhibitor (itraconazole) and a pan-CYP inducer (rifampin) on APX001 in two parallel groups of healthy subjects.
- Trial name
- NCT04166669
- Testing
- APX001, Itraconazole, Rifampin
- Where
- 2 sites in Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Critical Illness, Infection
Pharmacokinetics/Pharmacodynamics (PK/PD) of Caspofungin in Intensive Care Unit (ICU) Patients. An Open Observational Study for Antifungal Treatment's Optimization
PK of Caspofungin in ICU septic patients might be changed as compared to healthy volunteers due to sepsis-related pathophysiology.
- Trial name
- NCT03798600
- Testing
- Caspofungin
- Volunteers
- 20 people
- Sponsor
- Careggi Hospital
Tuberculosis, Pulmonary
A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2
The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.
- Trial name
- NCT04766307
- Testing
- Interleukin-2
- Where
- 16 sites in China
- Volunteers
- 1,100 people
- Sponsor
- Beijing Chest Hospital
HIV Infections, Tuberculosis
The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin
We believe that there is a strong rationale for the study of IDV/r 600/100 bid as a boosted-PI combination that, in the presence of RMP, is able to produce a satisfactory PK profile associated with adequate antiretroviral…
- Trial name
- NCT00411996
- Testing
- indinavir/ritonavir
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
AIDS, Tuberculosis
Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
The object of this study is to evaluate the pharmacokinetic interactions, short term safety and efficacy of standard dose lopinavir/ritonavir 200mg/50 (two tablets twice daily) given with ritonavir 100 mg three tablets twice…
- Trial name
- NCT01700790
- Testing
- Lopinavir/ritonavir and ritonavir
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- University of Miami
Neoplasms
Effect of Itraconazole on the Pharmacokinetics of Apatinib
he primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with itraconazole.
- Trial name
- NCT02836171
- Testing
- Apatinib Mesylate Tablets, Itraconazole Capsules
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Osteoarticular Infection
Treatment of Methicillin-sensitive Staphylococcus Aureus (MSSA)
Background: One of the leading causes of peri-operative osteoarticular infections (OAI) is Staphylococcus aureus. Treatment usually requires surgical debridement in association with appropriate antibiotic therapy.
- Trial name
- CLINDOS (NCT01500837)
- Testing
- association of RIFAMPIN + CLINDAMYCIN, association of LEVOFLOXACIN+ CLINDAMYCIN
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acquired Immunodeficiency Syndrome, Tuberculosis
Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
The purpose of this study is to determine the lopinavir levels in blood of HIV and TB infected children (3-15kg) when given lopinavir/ritonavir in a 1:1 ratio with rifampicin containing TB regimen and its safety.
- Trial name
- NCT02348177
- Testing
- lopinavir with ritonavir in 1:1 ratio, Lopinavir/ritonavir 4:1
- Where
- 5 sites in South Africa
- Volunteers
- 96 people
- Sponsor
- Drugs for Neglected Diseases